SCHEMBL2848307

SCHEMBL2848307

CN(C)S(=O)(=O)c1cccc(C(N)=O)c1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
RAB9A P51151 5/20 0.57
ALDH1A1 P00352 8/20 0.56
LMNA P02545 4/20 0.56
MAPT P10636 2/20 0.56
HTT P42858 1/20 0.56
NPC1 O15118 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TP53 P04637 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
GAA P10253 2/20 0.51
HSD17B10 Q99714 1/20 0.51
HPGD P15428 1/20 0.51
TSHR P16473 2/20 0.50
PARP1 P09874 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35185 0.84 MEN1 (0.65) MEN1KMT2ARAB9AALDH1A1LMNA
SCHEMBL3653439 0.84 MEN1 (0.65) MEN1KMT2ARAB9AALDH1A1LMNA
SCHEMBL29399627 0.84 MEN1 (0.65) MEN1KMT2ARAB9AALDH1A1LMNA
SCHEMBL2005622 0.83 MEN1 (0.63) MEN1KMT2ARAB9AALDH1A1LMNA
SCHEMBL2854838 0.82 SMN1; SMN2 (0.63) MEN1KMT2ARAB9AALDH1A1LMNA
SCHEMBL14712636 0.82 MEN1 (0.76) MEN1KMT2ARAB9AALDH1A1LMNA
SCHEMBL2852902 0.82 KMT2A (0.52) MEN1KMT2ARAB9AALDH1A1LMNA
SCHEMBL5035325 0.82 DPP4 (0.62) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL29503163 0.80 GAA (0.55) ALDH1A1LMNAMAPTSMN1; SMN2L3MBTL1
SCHEMBL31196958 0.80 GAA (0.55) ALDH1A1LMNAMAPTL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1761541-B1 PYRRAZOLO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-09 EP claimed
EP-1761541-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP claimed
WO-2005123738-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO claimed
CN-112153984-A Compound and use thereof 福宏治疗公司 2020-12-29 CN disclosed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
EP-1761541-B1 PYRRAZOLO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-09 EP disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
EP-1761541-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
WO-2005123738-A1 PYRRAZOLO-PYRIMIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 MEN1 4543/4885KMT2A 2659/4885RAB9A 3176/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 MEN1 4543/4885KMT2A 2659/4885RAB9A 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.